Cagrilintide + Semaglutide is a dual-agonist research pairing that targets complementary pathways in appetite control, energy regulation, and metabolic balance. Cagrilintide, a long-acting amylin analogue,
Reta (GLP-3) 10mg
$120.00Retatrutide is an investigational multi-agonist peptide engineered to activate three metabolic hormone receptors—GLP-1, GIP, and glucagon—positioning it as a next-generation “triple agonist.” In research settings, it has been
Reta (GLP-3) 20mg
$195.00Retatrutide is an investigational multi-agonist peptide engineered to activate three metabolic hormone receptors—GLP-1, GIP, and glucagon—positioning it as a next-generation “triple agonist.” In research settings, it has been
Reta (GLP-3) 30mg
$250.00Retatrutide is an investigational multi-agonist peptide engineered to activate three metabolic hormone receptors—GLP-1, GIP, and glucagon—positioning it as a next-generation “triple agonist.” In research settings, it has been
Sema (GLP-1) 10mg
$80.00Semaglutide is a long-acting GLP-1 receptor agonist (GLP-1RA) investigated for its effects on glycemic regulation and body-weight–related outcomes in controlled research settings. It is structurally optimized for extended
Sema (GLP-1) 20mg
$140.00Semaglutide is a long-acting GLP-1 receptor agonist (GLP-1RA) investigated for its effects on glycemic regulation and body-weight–related outcomes in controlled research settings. It is structurally optimized for extended
Sema (GLP-1) 30mg
$165.00Semaglutide is a long-acting GLP-1 receptor agonist (GLP-1RA) investigated for its effects on glycemic regulation and body-weight–related outcomes in controlled research settings. It is structurally optimized for extended
Tirz (GLP-2) 10mg
$105.00Tirzepatide is a long-acting synthetic polypeptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways, it has been
Tirz (GLP-2) 20mg
$165.00Tirzepatide is a long-acting synthetic polypeptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways, it has been
Tirz (GLP-2) 30mg
$205.00Tirzepatide is a long-acting synthetic polypeptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both incretin pathways, it has been
